EZH2 inhibitors enhance effectiveness of cancer immunotherapies

A study led by Weill Cornell Medicine researchers found that EZH2 inhibitors, a new class of anticancer drugs, could enhance the potency of cancer immunotherapies for non-Hodgkin B-cell lymphomas. The inhibitors target the EZH2 enzyme, known to be a significant factor in many cancers. Combining EZH2 inhibition with T-cell based immunotherapy was found to be more effective at shrinking lymphomas than immunotherapy alone. Preclinical trials have shown promising results with the combination of EZH2 inhibitors and T-cell immunotherapies, potentially improving the potency and durability of these treatments. This research could lead to new therapeutic targets for lymphoma patients.

Source link